Revenue grew 11% to ₹503 crore, while EBITDA improved 15.7% to ₹168 crore. Operating margins expanded to 33.5%, up from 32% in the year-ago quarter, reflecting improved cost efficiency and steady business momentum.
The board has declared an interim dividend of ₹3 per share (150%) for FY25 and fixed May 30, 2025 as the record date for determining eligible shareholders.
The company expects 13–14% topline growth in FY26, with EBITDA margins likely to stay within the 32–34% range.
Earlier in February, COO Vivek Partheeban had told CNBC-TV18 that the company expects consistent growth over the next 12–18 months, aided by ongoing expansion in the US market, the rising contribution from its oncology portfolio, and planned entries into Brazil and Mexico.
Also Read: Lupin Q4 Results: Revenue, EBITDA meet expectations; North America leads growth
Despite sourcing 28–30% of its supplies from China, the company remains confident of navigating short-term supply challenges while broadening its product pipeline.
Post earnings, shares of Caplin Point Laboratories were last seen trading 1.29% lower at ₹1,989.80 on the BSE.
First Published: May 15, 2025 1:52 PM IST
